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Altitude-related cough is a troublesome condition of uncertain aetiology that affects many visitors to high altitude.
The traditionally held belief that it was due solely to the inspiration of cold, dry air was refuted by observations and
experiments in long duration hypobaric chamber studies. It is likely that altitude-related cough is a symptom of a
number of possible perturbations in the cough reflex arc that may exist independently or together. These include
loss of water from the respiratory tract; respiratory tract infections and sub-clinical high altitude pulmonary oedema.
The published work on altitude-related cough is reviewed and possible aetiologies for the condition are discussed.Introduction
‘Alan was still racked by frequent coughs, and periodi-
cally, as if by auto-suggestion, I found that I too was
succumbing to a bout. Once started, there was no es-
cape. The cold dry air compounded the irritation in the
throat and the victim’s body would be shaken by the
hacking cough until randomly flung free of its spell. The
nights at base camp as well as on the mountain were
often punctuated by staccato bursts of noise disturbing
the sleep of the sufferer and all those around’.
This description by the late Joe Tasker is typical of the
debilitating, paroxysmal cough that is well known within
the mountaineering community to effect visitors to high
altitude [1-3]. Four members of the 1971 International
Himalayan Expedition to Mount Everest suffered rib
fractures as a result of coughing and other similar ac-
counts of cough-related rib fractures at high altitude
exist [2-4]. In a survey of 283 trekkers walking in the
Everest region of Nepal, 42% suffered from cough while
in another study, again in the Everest region of Nepal,
the prevalence of cough was found to be 22% between
4243 and 4937 m [5].
The first formal study of cough at high altitude took
place during the 1994 British Mount Everest Expedition
when 10 subjects trekking from 2800 m to Everest Base
Camp at 5300 m underwent nocturnal cough frequency
monitoring [6]. Nocturnal cough frequency increased
with increasing altitude. In three climbers in whom re-
cordings were made at 7000 m on Everest there was a
massive increase in nocturnal cough frequency (Figure 1).Correspondence: npmason@doctors.org.uk
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reproduction in any medium, provided the orAs part of the same study citric acid cough threshold was
measured in 42 subjects at sea level and on arrival at Base
Camp at 5300 m and again at Base Camp in 23 of these
same subjects after they had spent at least 9 days at or
above 5000 m. Citric acid cough threshold was unchanged
on arrival at Base Camp compared with sea level but was
significantly reduced on the second visit to Base Camp
compared with both the sea level and first visit to Base
Camp measurements. Despite both anecdotal and obser-
vational evidence of an increase in cough with altitude,
and a demonstrated change in citric acid cough threshold,
the aetiology of altitude-related cough is poorly under-
stood and treatment remains unsatisfactory.
Aetiology
Altitude-related cough has traditionally been attributed
to the inspiration of the cold, dry air which characterises
the high altitude mountain environment [2]. Interest-
ingly however, the author is not aware of any similar re-
ports in the polar exploration literature where exercising
explorers are exposed to a similar environment of cold,
dry air, but often at a considerably lower altitude. During
Operation Everest II eight subjects who underwent a
simulated ascent of Mount Everest in a hypobaric cham-
ber were decompressed over a 40 day period to a baro-
metric pressure of 253 mm Hg (33.7 kPa) equivalent to
the summit of Everest (8848 m). At altitudes above 7000
m the majority of the subjects developed pain and dry-
ness in the throat and an irritating cough, despite the
chamber being maintained at a relative humidity of
between 72 and 82% and a temperature of 23°C [7]. This
brought into question the widely held view that cough at
high altitude was due to the inspiration of dry, cold air.his is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Nocturnal cough frequency in 10 subjects during a
trek to Mount Everest Base Camp, Nepal (5300 m), including 3
climbers in whom recordings were made at 7000 m on Mount
Everest. Recordings were only possible in 3 subjects at between 4
and 5000 m due to logistical problems. The circled data point
represents a climber in whom the recorder suffered battery failure
after only 1 hour. Data plotted from [6].
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Everest III, during which 8 subjects again underwent a
simulated ascent of Mount Everest, Mason et al. [8]
studied nocturnal cough frequency and citric acid cough
threshold over the 40-day period of the study. During
the experiment the temperature and relative humidity of
the chamber were maintained at between 18 and 24°C
and 30-60% respectively. Nocturnal cough frequency in-
creased with increasing altitude and when the subjects
descended to 5000 m to recuperate before the ascent to
the “summit,” the cough frequency fell before increasing
again on ascent to 8000m. Cough frequency immedi-
ately returned to control values on descent to sea level.
This data is shown in Figure 2.
Citric acid cough threshold was measured at sea level,
5000 m, the return to 5000 m and at 8000m. There was noFigure 2 Nocturnal cough frequency in the eight subjects
taking part in Operation Everest III. R5000m: Return to 5000 m,
RSL: Return to Sea Level. Data plotted from [8].difference between either 5000 m or the return to 5000 m
and the sea level control, which may have been due to in-
adequate study power. A maximum of 8 people could be
accommodated in the hypobaric chamber, whereas power
calculations based on previous work [6] suggested that at
least 9 subjects would be required to detect a significant
fall in cough threshold. Cough threshold was however re-
duced at 8000 m compared to both sea level and the first
arrival at 5000 m, despite the constant environmental
humidity and temperature. The results of Operation
Everest III would thus appear to refute the idea that altitude-
related cough is due to the inspiration of dry, cold air.
If altitude-related cough is not simply due to the in-
spiration of dry, cold air, what might its aetiology be?
There are a number of potential mechanisms. Each will
be considered in turn:
– Acute mountain sickness (AMS).
– Sub-clinical high altitude pulmonary oedema.
– Changes in the central and peripheral control of
cough.
– Loss of water from the respiratory tract.
– Respiratory tract infections.
– Bronchoconstriction and asthma.
– Vasomotor-rhinitis and post-nasal drip.
– Gastro-oesophageal reflux.
Acute mountain sickness
Acute mountain sickness (AMS) is a common condition
that effects healthy individuals on ascent to altitude. The
incidence of AMS is dependent upon both the altitude and
speed of ascent [9]. Rarely people may be affected at alti-
tudes as low as 2000–2500 m while at altitudes between
3500 and 4500 m the reported incidence varies between 30
and 45% [10]. Symptoms normally appear several hours
after arrival at a new altitude and consist of a headache
and at least one other symptom from fatigue, dizziness,
gastrointestinal disturbance and difficulty sleeping. Peri-
pheral oedema is a common finding [11]. The symptoms,
which are probably due to mild cerebral oedema, may be
regarded as signs of slow acclimatization and normally will
disappear after 2–3 days at a given altitude, although they
may reappear on ascent to a new altitude. In severe cases
the boundary between AMS and high altitude cerebral
oedema (HACE) is blurred.
Despite both AMS and cough occurring commonly at
high altitude, there was no demonstrable relationship
between AMS and cough in any of the published papers
[6,8,12,13]. In subjects with isolated AMS cough is a
rarely reported symptom [9,11]. In 21 studies dealing
with AMS cough was not reported as a problem [14].
The inability to demonstrate a relationship between
altitude-related cough and AMS may reflect the inability
of the Lake Louise Scoring system [15], the standard tool
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detect early AMS. On balance however it seems unlikely
that AMS plays a significant role in the aetiology of
altitude-related cough.
Sub-clinical high altitude pulmonary oedema
High-altitude pulmonary oedema (HAPE) is a non-
cardiogenic, hydrostatic pulmonary oedema which oc-
curs predominantly in unacclimatised individuals up to
72 hours after ascent to a new altitude. The prevalence
depends upon the altitude, the rate of ascent and indi-
vidual susceptibility. Some individuals are susceptible to
developing the condition repeatedly on ascent to altitude
[16]. While these HAPE-susceptible individuals are fre-
quently studied they may not be representative of the
general population. The characteristic pathophysiological
finding in patients with HAPE is an abnormally elevated
pulmonary arterial pressor response to hypoxia with pul-
monary artery systolic pressures of around 60–80mmHg,
although values in excess of 140 mmHg have been reported
[16,17]. Reduction in this acute pulmonary hypertension
forms the mainstay of pharmacological therapy, used to
facilitate the definitive treatment: descent.
Although only a minority who go to high altitude de-
velop HAPE, some workers hypothesise that the major-
ity of people ascending to altitude may develop sub-
clinical pulmonary oedema. Evidence cited in favour of
this argument includes the fall in forced vital capacity
(FVC) on ascent to altitude [18]; changes in the phase
III slope (the alveolar plateau) of the nitrogen washout
curve [19,20] and clinical, radiological [21,22] and elec-
trical impedance tomography [23] changes consistent
with an increase in extra-vascular lung water, even in ap-
parently asymptomatic subjects. This view however is
not universally held [24].
The apparently simple question question as to whether
altitude-related cough could be a manifestation of sub-
clinical pulmonary oedema reveals the ongoing uncer-
tainty that exists regarding the identity of the afferent
pathways responsible for cough. It is still unclear as to
whether pulmonary oedema can cause cough in humans.
If it can, is there a sufficient stimulus in asymptomatic
subjects with subclinical pulmonary oedema at altitude
to activate such a pathway? Cough is not a common
clinical feature in cardiogenic pulmonary oedema. The
main anatomical sites that are responsible for cough are
located above the segmental airways (division 4) [25,26].
This is significantly more proximal than the airways in
which pulmonary oedema would begin to form [27]. Evi-
dence exists however from experiments in rabbits that
even small changes in left atrial pressure of between 2
and 5mmHg result in sufficient pulmonary venous con-
gestion as to stimulate airway rapidly adapting receptors
[28-30]. It is not known what these pressure changesequate to in humans but it is easy to imagine that pul-
monary artery pressures of between 35 and 45 mmHg
which have been reported in healthy control subjects
free of HAPE [31,32] could result in comparable pul-
monary venous congestion as an increase in left atrial
pressure of 2–5 mmHg.
The natural history of HAPE, which is associated
with a recent gain in altitude and improves drama-
tically with descent, is similar to the cough seen in Op-
eration Everest III [8]. However it is the author’s
experience that altitude-related cough can also be
present throughout a prolonged stay at one altitude
when acclimatisation would be well advanced and may
persist for a time after descent even to sea level. If
altitude-related cough was due to pulmonary oedema,
one might expect HAPE-susceptible subjects to have
more severe cough. This does not appear to be the
case. While it is attractive to speculate that sub-clinical
pulmonary oedema causes altitude-related cough, fur-
ther work, including interventional studies to assess
the impact of a reduction in pulmonary artery pressure
on altitude-related cough, is required before this hy-
pothesis can be confirmed or refuted.
The central control of cough
Respiratory control undergoes profound changes with
acclimatisation to high altitude [33]. The central control
of cough is complex [34-36] but there are a number of
factors which suppress cough that also suppress ventila-
tion, such as sleep [37,38] and centrally acting anti-
tussive agents [39]. Banner [40] demonstrated a relation-
ship between the hypercapnic ventilatory response
(HCVR) and the cough threshold to hypotonic saline,
with those subjects who responded to the hypotonic sa-
line challenge having a higher HCVR than the subjects
who did not respond. In addition Post-hoc analysis of
data from the 1994 British Mount Everest Medical Ex-
pedition demonstrated a relationship between the citric
acid cough threshold and the dynamic ventilatory re-
sponse to CO2 [41].
As a result of these findings Thompson et al. [13]
studied the relationship between the citric acid cough
threshold and the hypercapnic ventilatory response
(HCVR) in 25 healthy subjects during a 9 day stay at
5200 m. Citric acid cough threshold fell significantly on
ascent to altitude and the HCVR, measured using the
Read re-breathing method and expressed by the slope S,
increased significantly on ascent to 5200 m. This data is
shown in Figure 3. There was however no demonstrable
meaningful relationship between the citric acid cough
threshold and HCVR, or any change in these parame-
ters on ascent to altitude. It is therefore unlikely that
altitude-related cough is mediated through changes in
central control mechanisms.
Figure 3 Sample HCVR plot from subject at sea level and after
2 and 8 days at 5800m. Data from [13]. CVR is quantified by the
slope S and the end-tidal PCO2 for a ventilation of 15 l/min.
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While the neuronal pathways that mediate the citric acid
cough threshold remain debated they include stimula-
tion of airway sensory nerves including the rapidly
adapting receptor (RAR) [42]. Cough is a well recog-
nised side effect in a proportion of patients taking angio-
tensin converting enzyme (ACE) inhibitors and is
thought to be due to sensitisation of airway RARs by in-
creased levels of plasma bradykinin and substance P
[43]. Bradykinin is degraded by a number of enzymes
collectively known as kininases which include ACE, ami-
nopeptidase P and neutral endopeptidase and in human
serum over 75% of bradykinin metabolism occurs via
ACE [44,45]. The early literature on the response of
serum ACE activity to hypoxia in humans is confusing
and contradictory [46]. Nothing was known about what
happened to bradykinin at altitude beyond exposure to 1
hour of normobaric hypoxia [47].
Mason et al. [12] measured nocturnal cough frequency,
citric acid cough threshold, serum angiotensin converting
enzyme activity and plasma bradykinin concentration in
20 healthy volunteers before and during a stay at 3800
m. Citric acid cough threshold fell on ascent to 3800 m;
serum ACE activity was unchanged although plasma
bradykinin fell precipitously. It is not possible to meas-
ure lung ACE activity in living human subjects although
measurement of whole lung and serum ACE activity in
dogs during exposure to chronic hypoxia yielded com-
parable results [48]. Understandably no comparable data
exists in humans and the most likely explanation for these
findings is that serum ACE activity did not parallel an
increase in local tissue ACE activity in the pulmonary
endothelium [49]. Alternatively it is possible that bradyki-
nin was metabolised by a kininase other than ACE. The
kallikrein-kinin system is predominantly tissue based, and
tissue levels of bradykinin are known to exceed those in
blood, although in rats changes in plasma levels of brady-
kinin have been shown to parallel changes in the tissues[50]. A further weakness of this study is that although
citric acid cough threshold fell, suggesting an increased
sensitivity of the afferent cough reflex arc, there was no
increase in the clinical incidence of cough as measured
by the nocturnal cough frequency. It thus remains diffi-
cult to draw any meaningful conclusion about the role
that the kallikrein-kinin system may play in the aeti-
ology of altitude-related cough.
Respiratory water loss
It is still possible, despite the increase in nocturnal cough
frequency and decrease in citric acid cough threshold ob-
served under the controlled environmental conditions of
Operation Everest III [8] that water loss from the respira-
tory tract plays a role in the aetiology of altitude-related
cough. Banner et al. [51] studied subjects susceptible to
exercise-induced cough and found that hyperpnoea for 4
minutes with cold air, at respiratory rates similar to those
occurring with strenuous exercise, was associated with an
increase in cough frequency in the 30 minute period post-
hyperpnoea. Bronchoconstriction was blocked using in-
haled β2 agonists and there was no evidence of bronchial
hyper-reactivity to a methacholine challenge. In a follow
up study, subjects susceptible to exercise-induced cough
underwent voluntary isocapnic hyperpnoea to over 90
litres/minute with a variety of inspired air conditions [52].
Cough frequency was found to depend directly upon
respiratory water loss in a linear manner and that in the
absence of water loss, even in the presence of heat loss,
cough frequency did not increase. Hyperpnoea with
warm, dry air produced more coughing than hyperp-
noea with cold air despite less heat loss. Hyperpnoea
with ambient air produced as great an increase in cough
frequency as hyperpnoea with cold air because it was
associated with significant water loss. These findings
are illustrated in Figure 4.
These findings raise the possibility that, at least in a
subgroup of sufferers, altitude-related cough may be
caused by water loss from the respiratory tract. How
this water loss might stimulate afferent cough pathways
is not known but possible mechanisms include physical
distortion of afferent nerve endings [53] and changes in
the ionic composition of airway surface liquid [54]. In-
creased minute ventilation plays a key role in respira-
tory acclimatisation to hypobaric hypoxia, increasing
with increasing altitude and further still with exercise
[33]. It is thus possible that despite controlling the en-
vironmental conditions during Operation Everest III [8]
respiratory water loss could have contributed to the in-
crease in cough frequency and sensitivity seen. The data
on respiratory water loss at altitude is very limited and
confined to subjects who were exercising [55]. In the
Operation Everest II and III chamber studies the sub-
jects were mainly sedentary.
Figure 4 Number of coughs in excess of baseline (Cough);
respiratory water loss (RWE) and respiratory heat loss (RHE) in
7 subjects with exercise-induced cough during a 19 minute
period after 4 minutes of hyperpnoea with cold air at -16ºC or
warm, dry air at 38.7ºC. Both the cold air and the warm dry air
had a water content of 0 g m-3. From [60].
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There is evidence of subjective nasal blockage and an in-
crease in nasal resistance at altitude which will likely
result in increased mouth breathing [56,57]. Water loss
is known to increase during mouth, rather than nasal
breathing [58].
Respiratory tract infections
Respiratory tract infections are the commonest cause of
acute cough at sea level [59,60]. Signs and symptoms of
respiratory tract infection also occur commonly in visitors
to altitude [61,62] in whom there is also evidence of im-
pairment of mucociliary transport - a crucial respiratory
defence mechanism [56]. There was no clinical evidence
of respiratory infection observed in any of the published
studies on altitude-related cough [6,8,12,13]. However in
the author’s experience cough associated with the produc-
tion of purulent sputum is not an uncommon finding at
altitude, particularly following prolonged exertion. This
cough responds poorly to antibiotics. Whether this argues
against a bacterial aetiology is unclear although prolonged
cough following relatively minor atypical bacterial respi-
ratory infections are well recognised at sea level [63,64].
Viral infections are also a well recognised cause of cough
at sea level [65] but no data exists on their prevalence at
high altitude. Further work is required on the microbio-
logy of respiratory tract infections in visitors to altitude
and their relationship to cough.
Bronchoconstriction
Cough may be the only presenting symptom of asthma
[66,67]. Bronchoconstriction can occur in both asthmatics
and healthy subjects on exposure to cold air. The me-
chanism for this appears to be due to water loss from therespiratory tract rather than a direct effect of temperature
on the airways [68]. There was no change in FEV1 or PEF
associated with the fall in citric acid cough threshold at ei-
ther Everest Base Camp [6] or during Operation Everest
III [8]. Although both acute hypoxia and hypocapnia have
been shown to cause bronchoconstriction in animal
models [69-71], Pollard et al. [72] could demonstrate no
evidence of bronchoconstriction in healthy lowland sub-
jects at Everest Base Camp. Likewise Dehnert et al. [24]
demonstrated no change in either effective or specific air-
way resistance on ascent to 4559 m. It is unlikely that
bronchoconstriction plays a major role in altitude-related
cough in non-asthmatic subjects.
Vasomotor rhinitis and post-nasal drip
Upper airway cough syndrome (previously known as
post-nasal drip syndrome) is one of the most common
causes of chronic cough [73]. Nasal blockage and symp-
toms of rhinitis are common complaints at altitude
[56,61] but their relationship with cough, if any, has not
been established.
Gastro-oesophageal reflux
Gastro-oesophageal reflux has been reported in up to
40% of patients with chronic cough at sea level [74-76]
but nothing is known about its prevalence at altitude.
Changes in nebuliser output at altitude
A potential cause for the change in citric acid cough
threshold seen on exposure to hypobaric hypoxia would
be an alteration in nebuliser output consequent upon
the reduced barometric pressure. Barry studied the out-
put of 3 types of nebulisers in a hypobaric chamber up
to an altitude equivalent of 5300 m [77]. The output of
salbutamol from both a conventional jet nebuliser and a
breath enhanced nebuliser, collected onto a filter, fell by
over 50% at simulated altitude compared with sea level,
while the output of an ultrasonic nebuliser fell by only
23% at 4200 m and 13% at 5300 m. Subsequently Barry
et al. [78] measured serum salbutamol levels in human
subjects following nebulised administration of salbuta-
mol via an ultrasonic nebuliser at both sea level and a
simulated altitude of 5000 m in a hypobaric chamber.
There was no difference in serum salbutamol levels be-
tween the 2 altitudes. Providing an ultrasonic nebuliser
is used at altitude, as has been the case in all of the pub-
lished studies [6,8,12,13], it seems unlikely that the in-
crease in sensitivity to citric acid can be explained by
alterations in nebuliser output.
Current understanding of altitude-related cough
Our current understanding of the epidemiology and aeti-
ology of altitude-related cough remains limited. From
the published work, to date, the only conclusions that
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its prevalence increases with increasing altitude; it is as-
sociated with a decrease in the citric acid cough thres-
hold; is not solely due to the inspiration of dry, cold air,
as has traditionally been thought, and the increased sen-
sitivity to inhaled citric acid does not appear to be re-
lated to the changes in the central control of ventilation
that occur with acclimatisation.
Exploration of the aetiology of altitude-related cough
has been limited by the logistical difficulty of carrying
out robust research in the high altitude environment
[79] or in hypobaric chambers [80]. These difficulties
will be only too apparent to those who have worked in
this hostile environment and something of a mystery to
those who have not. While altitude-related cough un-
doubtedly exists, one of the problems in the published
work, is the lack of a consistent relationship between the
sensitivity to inhaled citric acid and the clinical presence
of cough, as assessed by nocturnal cough frequency.
Nocturnal cough frequency increased on arrival at Ever-
est Base Camp but was not accompanied by a fall in a
citric acid cough threshold [6]. Conversely citric acid
cough threshold fell at the relatively low altitude of 3800
m but was not accompanied by any change in nocturnal
cough frequency [12]. These conflicting results are un-
doubtedly compounded by the small number of subjects
in the published studies which is also the likely explan-
ation of the difficulty in demonstrating a significant
change in cough frequency or citric acid cough threshold
below altitudes of 7000 m [6,8] despite, anecdotally,
cough being a clinical problem at lower altitudes.
It seems most likely that, as at sea level, altitude-
related cough is a symptom of a number of possible
perturbations in the cough reflex arc that may exist in-
dependently or together. The most likely aetiological
factors are infection or water loss from the respiratory
tract leading to trauma of the respiratory mucosa and
tracheo-bronchitis, and sub-clinical pulmonary oedema.
Respiratory water loss and sub-clinical pulmonary
oedema could both be precipitated or worsened by
exercise. Future work should investigate the role of
these aetiologies as well as quantifying the prevalence
of altitude-related cough in larger populations at alti-
tude and to correlate better the relationship between
clinical cough and inspired tussive challenges.Competing interests
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